Press Releases BeOne Medicines AG

Stocks

ONC

US07725L1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 08:36:56 15/06/2026 pm IST			5-day change	1st Jan Change
265.96 ^USD	+0.56%		-1.47%	-12.17%

12/06	BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses	MT
12/06	BeOne Medicines Announces New Data From Foundational Hematology Franchise At EHA 2026	CI

Press Releases

12/06	BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026	BU
11/06	BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit	BU
01/06	BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026	BU
29/05	BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026	BU
28/05	BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026	BU
26/05	BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	BU
21/05	BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts	BU
20/05	BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard	BU
13/05	BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma	BU
06/05	BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates	BU
29/04	U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA	BU
28/04	BeOne Medicines : Proxy Materials for Annual General Meeting (2026 Proxy Statement)	PU
28/04	BeOne Medicines : Proxy Materials for Annual General Meeting (2026 Proxy Card)	PU
22/04	BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6	BU
14/04	BeOne Medicines : 2025 Responsible Business & Sustainability Report	PU
26/02	BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership	BU
17/02	BeOne Medicines to Present at Upcoming Investor Conferences	BU
11/02	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26	BU
13/01	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference	BU
07/01	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA	BU
06/01	BeOne Medicines : rsquo; Novel BCL2 Inhibitor, Sonrotoclax, Achieves First-in-World Approval in R/R MCL and R/R CLL/SLL	PU
23/12	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
18/12	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma	BU
08/12	BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia	BU
08/12	Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies	BU